Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL™ (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-α2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.
1. A complex comprising:
(a) an anti-IGF-1R (insulin-like growth factor type I receptor) IgG antibody attached to an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP), wherein the anti-IGF-1R antibody comprises the heavy chain CDR sequences: CDR1 having the amino acid sequence DYYMY (SEQ ID NO:85), CDR2 having the amino acid sequence YITNYGGSTYYPDTVKG (SEQ ID NO:86) and CDR3 having the amino acid sequence QSNYDYDGWFAY (SEQ ID NO:87) and the light chain CDR sequences: CDR1 having the amino acid sequence KASQEVGTAVA (SEQ ID NO:88), CDR2 having the amino acid sequence WASTRHT (SEQ ID NO:89) and CDR3 having the amino acid sequence QQYSNYPLT (SEQ ID NO:90); and
(b) two copies of a fusion protein, each fusion protein comprising an effector attached to one copy of a dimerization and docking domain (DDD) moiety from a human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ; wherein the effector is a cytokine or a F(ab′) 2 , Fab, Fab′ or scFv from a second antibody.
2. The complex of claim 1 , wherein the second antibody binds to a tumor-associated antigen selected from the group consisting of carbonic anhydrase IX, CSAp (colon-specific antigen-p), CD1 (cluster of differentiation 1), CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20, IGF-1R, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a, CD66b, CD66c, CD66d, CD66e, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5), CEACAM6, ED-B (extradomain B) of fibronectin, Factor H, FHL-1 (four and a half LIM domains protein 1), Flt-3 (Fms-like tyrosine kinase 3), folate receptor, GRO-β (growth regulatory oncogene beta), HMGB-1 (high mobility group protein B1), hypoxia inducible factor (HIF), HM1.24, insulin-like growth factor-1 (ILGF-1), IFN-γ (interferon-gamma), IFN-α, IFN-β, IL-2 (interleukin-2), IL-4R (interleukin-4 receptor), IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10 (interferon gamma-induced protein 10), MAGE (melanoma antigen), mCRP (modified C-reactive protein), MCP-1 (monocyte chemoattractant protein-1), MIP-1A (macrophage inflammatory protein-1A), MIP-1B, MIF (macrophage migration inhibitory factor), MUC1 (mucin 1), MUC2, MUC3, MUC4, MUC5ac, NCA-95 (normal glycoprotein crossreacting with CEA-95), NCA-90, PSMA (prostate-specific membrane antigen), EGP-1 (epithelial/carcinoma antigen-1), EGP-2, AFP (alpha fetoprotein), HLA-DR (human leukocyte antigen-DR), tenascin, Le(y) (Lewis antigen y), RANTES(regulated on activation, normal T cell expressed and secreted), Tn (Thomsen-nouvelle) antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, TNF-α (tumor necrosis factor-alpha), TRAIL (TNF-related apoptosis-inducing ligand) receptor R1, TRAIL receptor R2, VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor), P1GF (placental growth factor), complement factor C3, complement factor C3a, complement factor C3b, complement factor C5a, complement factor C5, and an oncogene product.
3. The complex of claim 1 , wherein the cytokine is selected from the group consisting of human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, tumor necrosis factor-α, tumor necrosis factor-β, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin (TPO), NGF-β, platelet-growth factor, TGF-α, TGF-β, insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, an interferon, interferon-α, interferon-β, interferon-γ, macrophage-CSF (M-CSF), IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-25, kit-ligand, angiostatin, thrombospondin, and endostatin.
4. The complex of claim 1 , wherein the cytokine is interferon-α2b.
5. The complex of claim 1 , wherein the anti-IGF-1R antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:94 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:95.
6. The complex of claim 1 , wherein the anti-IGF-1R antibody is a chimeric antibody or a humanized antibody.
7. The complex of claim 1 , wherein the antibody comprises an Fc region capable of inducing effector function, wherein the complex is effective in treating a cancer that expresses human IGF-1R.
8. The complex of claim 7 , wherein the cancer is selected from the group consisting of Wilms' tumor, Ewing sarcoma, a neuroendocrine tumor, a glioblastoma, a neuroblastoma, a melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, renal cancer, pancreatic cancer, lung cancer, biliary cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid carcinoma, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and urinary bladder cancer.
9. The complex of claim 7 , wherein the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
10. The complex of claim 1 , further comprising a therapeutic agent selected from the group consisting of a radionuclide, an immunomodulator, an anti-angiogenic agent, a cytokine, a chemokine, a growth factor, a hormone, a drug, a prodrug, an enzyme, a pro-apoptotic agent, a photoactive therapeutic agent, a cytotoxic agent, a chemotherapeutic agent and a toxin, wherein the therapeutic agent is conjugated to the complex.
11. The complex of claim 10 , wherein the drug is selected from the group consisting of 5-fluorouracil, azaribine, anastrozole, anthracyclines, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin (CDDP), Cox-2 inhibitors, irinotecan (CPT-11), SN-38, cladribine, camptothecans, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, estramustine, epipodophyllotoxin, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-d0), fludarabine, flutamide, farnesyl-protein transferase inhibitors, gemcitabine, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, lenolidamide, leucovorin, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, nitrosourea, plicomycin, procarbazine, paclitaxel, pentostatin, PSI-341, raloxifene, semustine, streptozocin, tamoxifen, temazolomide, transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinorelbine, vinblastine, vincristine and vinca alkaloids.
12. The complex of claim 10 , wherein the toxin is selected from the group consisting of ricin, abrin, saporin, ribonuclease (RNase), ranpirnase DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.
13. The complex of claim 10 , wherein the radionuclide is selected from the group consisting of 111 In, 177 Lu, 212 Bi, 213 Bi, 211 At, 62 Cu, 67 Cu, 90 Y, 125 I, 131 I, 32 P, 33 P, 47 Sc, 111 Ag, 67 Ga, 142 Pr, 153 Sm, 161 Tb, 166 Dy, 166 Ho, 186 Re, 188 Re, 189 Re, 212 Pb, 223 Ra, 225 Ac, 59 Fe, 75 Se, 77 As, 89 Sr, 99 Mo, 105 Rh, 109 Pd, 143 Pr, 149 Pm, 169 Er, 194 Ir, 198 Au, 199 Au, and 211Pb.
14. A composition comprising the complex of claim 1 and a buffer.
15. A complex comprising:
(a) an anti-IGF-1R antigen-binding antibody fragment attached to an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP), wherein the anti-IGF-1R antigen-binding antibody fragment comprises the heavy chain CDR sequences: CDR1 having the amino acid sequence DYYMY (SEQ ID NO:85), CDR2 having the amino acid sequence YITNYGGSTYYPDTVKG (SEQ ID NO:86) and CDR3 having the amino acid sequence QSNYDYDGWFAY (SEQ ID NO:87) and the light chain CDR sequences: CDR1 having the amino acid sequence KASQEVGTAVA (SEQ ID NO:88), CDR2 having the amino acid sequence WASTRHT (SEQ ID NO:89) and CDR3 having the amino acid sequence QQYSNYPLT (SEQ ID NO:90); and
(b) two copies of a fusion protein, each fusion protein comprising an effector attached to one copy of a dimerization and docking domain (DDD) moiety from a human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ; wherein the effector is a cytokine or a F(ab′) 2 , Fab, Fab′ or scFv from a second antibody.
16. The complex of claim 15 , wherein the second antibody binds to a tumor-associated antigen selected from the group consisting of carbonic anhydrase IX, CSAp (colon-specific antigen-p), CD1 (cluster of differentiation 1), CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20, IGF-1R, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a, CD66b, CD66c, CD66d, CD66e, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5), CEACAM6, ED-B (extradomain B) of fibronectin, Factor H, FHL-1 (four and a half LIM domains protein 1), Flt-3 (Fms-like tyrosine kinase 3), folate receptor, GRO-β (growth regulatory oncogene beta), HMGB-1 (high mobility group protein B1), hypoxia inducible factor (HIF), HM1.24, insulin-like growth factor-1 (ILGF-1), IFN-γ (interferon-gamma), IFN-α, IFN-β, IL-2 (interleukin-2), IL-4R (interleukin-4 receptor), IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10 (interferon gamma-induced protein 10), MAGE (melanoma antigen), mCRP (modified C-reactive protein), MCP-1 (monocyte chemoattractant protein-1), MIP-1A (macrophage inflammatory protein-1A), MIP-1B, MIF (macrophage migration inhibitory factor), MUC1 (mucin 1), MUC2, MUC3, MUC4, MUC5ac, NCA-95 (normal glycoprotein crossreacting with CEA-95), NCA-90, PSMA (prostate-specific membrane antigen), EGP-1 (epithelial/carcinoma antigen-1), EGP-2, AFP (alpha fetoprotein), HLA-DR (human leukocyte antigen-DR), tenascin, Le(y) (Lewis antigen y), RANTES(regulated on activation, normal T cell expressed and secreted), Tn (Thomsen-nouvelle) antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, TNF-α (tumor necrosis factor-alpha), TRAIL (TNF-related apoptosis-inducing ligand) receptor R1, TRAIL receptor R2, VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor), PlGF (placental growth factor), complement factors C3, complement factor C3a, complement factor C3b, complement factor C5a, complement factor C5, and an oncogene product.
17. The complex of claim 15 , wherein the cytokine is selected from the group consisting of human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, tumor necrosis factor-α, tumor necrosis factor-β, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin (TPO), NGF-β, platelet-growth factor, TGF-α, TGF-β, insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factors, an interferon, interferon-α, interferon-β, interferon-β, macrophage-CSF (M-CSF), IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-25, kit-ligand, angiostatin, thrombospondin, and endostatin.
18. The complex of claim 15 , wherein the cytokine is interferon-α2b.
19. The complex of claim 15 , wherein the anti-IGF-1R or antigen-binding antibody fragment comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:94 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:95.
20. The complex of claim 15 , wherein the anti-IGF-1R antigen-binding antibody fragment comprises an Fc region capable of inducing effector function, wherein the complex is effective in treating a cancer that expresses human IGF-1R.
21. The complex of claim 20 , wherein the cancer is selected from the group consisting of Wilms' tumor, Ewing sarcoma, a neuroendocrine tumor, a glioblastoma, a neuroblastoma, a melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, renal cancer, pancreatic cancer, lung cancer, biliary cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid carcinoma, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and urinary bladder cancer.
22. The complex of claim 20 , wherein the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
23. The complex of claim 15 , further comprising a therapeutic agent selected from the group consisting of a radionuclide, an immunomodulator, an anti-angiogenic agent, a cytokine, a chemokine, a growth factor, a hormone, a drug, a prodrug, an enzyme, a pro-apoptotic agent, a photoactive therapeutic agent, a cytotoxic agent, a chemotherapeutic agent and a toxin, wherein the therapeutic agent is conjugated to the complex.
24. The complex of claim 23 , wherein the drug is selected from the group consisting of 5-fluorouracil, azaribine, anastrozole, anthracyclines, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin (CDDP), Cox-2 inhibitors, irinotecan (CPT-11), SN-38, cladribine, camptothecans, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, estramustine, epipodophyllotoxin, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, gemcitabine, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, lenolidamide, leucovorin, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, nitrosourea, plicomycin, procarbazine, paclitaxel, pentostatin, PSI-341, raloxifene, semustine, streptozocin, tamoxifen, temazolomide, transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinorelbine, vinblastine, vincristine and vinca alkaloids.
25. The complex of claim 23 , wherein the toxin is selected from the group consisting of ricin, abrin, saporin, ribonuclease (RNase), ranpirnase DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.
26. The complex of claim 23 , wherein the radionuclide is selected from the group consisting of 111 In, 177 Lu, 212 Bi, 213 Bi, 211 At, 62 Cu, 67 Cu, 90 Y, 125 I, 131 I, 32 , P, 32 P, 47 Sc, 111 Ag, 67 Ga, 142 Pr, 153 Sm, 161 Tb, 166 Dy, 166 Ho, 186 Re, 188 Re, 189 Re, 212 Pb, 223 Ra, 225 Ac, 59 Fe, 75 Se, 77 As, 89 Sr, 99 Mo, 105 Rh, 109 Pd, 143 Pr, 149 Pm, 169 Er, 194 Ir, 198 Au, 199 Au, and 211 Pb.
27. A composition comprising the complex of claim 15 and a buffer.